CureVac and Fareva Sign Agreement For Fill & Finish Manufacturing of Curevac’s COVID-19 Vaccine Candidate, CVnCoV
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Fareva today announced an agreement regarding the fill & finish manufacturing of CureVac´s COVID-19 vaccine candidate, CVnCoV, at Fareva’s Pau and Val-de-Reuil-sites in France.